Yayınlar & Eserler

Yayın Ağı
Makaleler 83
Tümü (83)
SCI-E, SSCI, AHCI (72)
SCI-E, SSCI, AHCI, ESCI (77)
ESCI (5)
Scopus (79)
TRDizin (3)
Diğer Yayınlar (4)

1. Application of response surface methodology and quality by design to [68Ga]Ga-PSMA-11 preparation

Pehlivanoglu H., Ocak M., ÇAĞLAR ANDAÇ S.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY , cilt.333, sa.1, ss.43-51, 2024 (SCI-Expanded) identifier identifier

2. Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer

Alan-Selcuk N., Beydagi G., Demirci E., OCAK DEMİRCİ E. M., Celik S., Oven B. B., et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine , cilt.64, sa.10, ss.1574-1580, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

3. Prevalence, comorbidities and mediators of childhood anxiety disorders in urban Turkey: a national representative epidemiological study

Mutluer T., Görker I., Akdemir D., Özdemir D., Ozel O. O., Vural P., et al.
Social Psychiatry and Psychiatric Epidemiology , cilt.58, sa.6, ss.919-929, 2023 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

4. Development and validation of a UV-Radio-HPLC method to assess chemical and radiochemical purity of [68Ga] Ga-PSMA-11

Pehlivanoglu H., Ocak M., Caglar-Andac S.
APPLIED RADIATION AND ISOTOPES , cilt.190, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

5. Value of Personalized Radiation Absorbed Dose Calculation for Radioiodine Ablation Therapy

Sahin O., Selcuk N. A., Yeyin N., Akyel R., Toklu T., Beytur M. F., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.49, sa.SUPPL 1, 2022 (SCI-Expanded) identifier

6. Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)

Beydagi G., Selcuk N. A., Demirci E., Ocak M., Toklu T., Akcay K., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.49, sa.SUPPL 1, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

7. The Role of [Ga-68]Ga-DOTA-FAPI-04 PET/CT on Altering Stage in Patients with Non-FDG-avid Lesions

Beydagi G., Selcuk N. A., Demirci E., Akcay K., Oven B., Celik S., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.49, sa.SUPPL 1, 2022 (SCI-Expanded) identifier

8. Peptide-Receptor Radionuclide Therapy (PRRT) with 225Ac-DOTA-TATE: Initial Results and Contribution to Progression-Free Survival

Beydagi G., Demirci E., Selcuk N. A., Ocak M., Toklu T., Akcay K., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.49, sa.SUPPL 1, 2022 (SCI-Expanded) identifier

9. Contribution of PSMA PET/CT to Evaluation of Response to Systemic Therapies: Preliminary Results

Beydagi G., Demirci E., Selcuk N. A., Akcay K., Ocak M., Toklu T., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.49, sa.SUPPL 1, 2022 (SCI-Expanded) identifier

10. EANM guideline on quality risk management for radiopharmaceuticals

Gillings N., Hjelstuen O., Behe M., Decristoforo C., Elsinga P. H., Ferrari V., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.49, sa.10, ss.3353-3364, 2022 (SCI-Expanded) Creative Commons License identifier identifier identifier

11. Almost Complete Response with a Single Administration Ac-225-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

ALAN SELÇUK N., Demirci E., Ocak M., Toklu T., Ergen S., KABASAKAL L.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , cilt.31, sa.2, ss.139-141, 2022 (ESCI) Creative Commons License identifier identifier identifier identifier

12. Ga-[68]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach

Alan Selçuk N., Ergen S., Demirci E., Ocak M., Kabasakal L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.48, sa.13, ss.4523-4524, 2021 (SCI-Expanded) identifier identifier identifier

13. Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT

Asa S., Sönmezoğlu K., Uslu-Besli L., Sahin O. E., Karayel E., Pehlivanoglu H., et al.
ANNALS OF NUCLEAR MEDICINE , cilt.35, ss.900-915, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

14. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals

Gillings N., Hjelstuen O., Ballinger J., Behe M., Decristoforo C., Elsinga P., et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY , cilt.6, sa.1, 2021 (ESCI) Sürdürülebilir Kalkınma identifier identifier identifier

15. The Role of (68)GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy

Gültekin M. H., Demirci E., Turegun F. A., Kabasakal L., Sahin O. E., Ocak M., et al.
UROLOGY JOURNAL , cilt.18, sa.1, ss.58-65, 2021 (SCI-Expanded) identifier identifier identifier

16. Formulation development and evaluation of taste-masked atomoxetine hydrochloride orally disintegrating tablets (Odts)

Kazaz Ç., Mesut B., Özsoy Y., Ocak E. M.
Journal of Research in Pharmacy , cilt.25, sa.5, ss.715-727, 2021 (ESCI) identifier identifier identifier

17. Recent Developments of Radiopharmaceuticals for Neuroendocrine Tumor Imaging and Therapy

OCAK E. M.
NUCLEAR MEDICINE SEMINARS , cilt.7, 2021 (Hakemli Dergi)

18. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor

Ocak M., Toklu T., Demirci E., Selçuk N., Kabasakal L.
European Journal of Nuclear Medicine and Molecular Imaging , cilt.47, sa.11, ss.2711-2712, 2020 (SCI-Expanded) identifier identifier identifier

19. Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria

Demirci E., Akyel R., Caner B., Alan-Selçuk N., Güven-Meşe Ş., Ocak M., et al.
Nuclear medicine communications , cilt.41, sa.8, ss.759-767, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

20. EANM guideline on the validation of analytical methods for radiopharmaceuticals.

Gillings N., Todde S., Behe M., Decristoforo C., Elsinga P., Ferrari V., et al.
EJNMMI radiopharmacy and chemistry , cilt.5, ss.7, 2020 (ESCI) Sürdürülebilir Kalkınma identifier identifier identifier

21. Performance of f-18 fluorocholine PET/CT for detection of hyperfunctioning parathyroid tissue in patients with elevated parathyroid hormone levels and negative or discrepant results in conventional imaging

Uslu-Beşli L., Sonmezoglu K., Teksoz S., Akgun E., Karayel E., Pehlivanoglu H., et al.
Korean Journal of Radiology , cilt.21, sa.2, ss.236-247, 2020 (SCI-Expanded) identifier identifier identifier

22. Formulation design and taste assessment in orally disintegrating tablets Ağızda dağılan tabletlerde formülasyon tasarımı ve tat değerlendirilmesi

KAZAZ Ç., Ocak M., MESUT B., Özsoy Y.
Fabad Journal of Pharmaceutical Sciences , cilt.44, sa.2, ss.169-178, 2019 (Scopus) Sürdürülebilir Kalkınma identifier

23. ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM Ga-68-PSMA-11 PET SCAN

Demirci E. M., Toklu T., Yeyin N., Ocak M., Alan-Selcuk N., Araman A., et al.
RADIATION PROTECTION DOSIMETRY , cilt.182, sa.4, ss.518-524, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

24. Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update

Demirci E., Kabasakal L., Toklu T., Ocak M., Şahin O. A., Alan-Selcuk N., et al.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.39, sa.8, ss.789-796, 2018 (SCI-Expanded) identifier identifier identifier

25. Cu-64-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases

Ocak M., Beaino W., White A., Zeng D., CAI Z., ANDERSON C. J.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS , cilt.33, sa.2, ss.74-83, 2018 (SCI-Expanded) identifier identifier identifier

26. Comparison of F-18 DOPA and Ga-68 DOTA TATE in detection of recurrences or metastasis of medullary thyroid cancer

Asa S., Sonmezoglu K., Akgun E. K., Khosroshah S. R., Toksoz S., Pehlivanoglu H., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.44, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

27. Extracting more information from Ga-68-PSMA-11 PET/CT performed for primary staging of prostate cancer

Sahin O., Akgun E. K., Demirci E., Ocak M., Aygun A., Pehlivanoglu H., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.44, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

28. Comparison of F-18 Choline PET/CT with Tc-99m MIBI and USG for Detection of Parathyroid Adenomas in Patients with Elevated Parathyroid Hormone Levels: Preliminary Results

Uslu-Beli L., Sonmezoglu K., Akgun E. K., Teksoz S., Karayel E., Pehlivanoglu H., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.44, 2017 (SCI-Expanded) identifier

29. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer

Obek C., DOGANCA T., Demirci E., Ocak M., Kural A. R., YILDIRIM A., et al.
European Journal of Nuclear Medicine and Molecular Imaging , cilt.44, sa.11, ss.1806-1812, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

30. Efficacy and Safety of 177Lu-PSMA-617 Treatment in Castration Resistant Prostate Cancer with Organ Metastasis

Sahin O. E., Akgun E., Demirci E., Ocak M., Akgun A., Akovali B., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.44, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

31. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry

Kabasakal L., Toklu T., Yeyin N., Demirci E., Abuqbeitah M., Ocak M., et al.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY , cilt.26, sa.2, ss.62-68, 2017 (ESCI) Sürdürülebilir Kalkınma identifier identifier identifier

32. Guidance on validation and qualification of processes and operations involving radiopharmaceuticals

Todde S., Kolenc Peitl P., Elsinga P., Koziorowski J., Ferrari V., OCAK M., et al.
EJNMMI Radiopharmacy and Chemistry , sa.2, ss.1-29, 2017 (Scopus)

33. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels

Kabasakal L., Demirci E., Nematyazar J., Akyel R., Razavi B., Ocak M., et al.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.38, sa.2, ss.149-155, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

34. Preclinical Evaluation of F-18-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors

Demirci E., Ahmed R., Ocak M., Latoche J., Radelet A., DeBlasio N., et al.
MOLECULAR IMAGING , cilt.16, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

35. The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results.

Sonmezoglu K., Vatankulu B., Elverdi T., Akyel R., Erkan M. E., Halac M., et al.
Nuclear medicine communications , cilt.38, sa.1, ss.76-83, 2017 (SCI-Expanded) identifier identifier identifier

36. Normal distribution pattern and physiological variants of Ga-68-PSMA-11 PET/CT imaging

Demirci E., Sahin O. E., Ocak M., Akovali B., Nematyazar J., Kabasakal L.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.37, sa.11, ss.1169-1179, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

37. Normal Distribution Pattern and Physiological Variants of Ga-68-PSMA PET/CT

Demirci E., Sahin O. E., Ocak M., Akovali B., Kabasakal L.
JOURNAL OF NUCLEAR MEDICINE , cilt.57, 2016 (SCI-Expanded) identifier

38. Preparation and in-vivo evaluation of dimenhydrinate buccalmucoadhesive films with enhanced bioavailability

Pekoz A., Erdal M. S., Okyar A., Ocak M., Tekeli F., Kaptan E., et al.
Drug Development and Industrial Pharmacy , cilt.42, sa.6, ss.916-925, 2016 (SCI-Expanded) identifier identifier identifier

39. Pre-therapeutic dosimetry of normal organs and tissues of Lu-177-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer

Kabasakal L., AbuQbeitah M., Aygun A., Yeyin N., Ocak M., Demirci E., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.42, sa.13, ss.1976-1983, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

40. Evaluation of PSMA PET/CT imaging using a Ga-68-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging

Kabasakal L., Demirci E., Ocak M., Akyel R., Nematyazar J., Aygun A., et al.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.36, sa.6, ss.582-587, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

41. PET Radyofarmasötikleri

OCAK M.
Toraks Cerrahisi Bülteni , cilt.6, sa.2, ss.154-160, 2015 (Hakemli Dergi)

42. Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model

Ocak M., GILLMAN A. G., Bresee J., Zhang L., VLAD A. M., Mueller C., et al.
MOLECULAR PHARMACEUTICS , cilt.12, sa.2, ss.542-553, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

43. Ga-68-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma

Demirci E., Ocak M., Kabasakal L., Decristoforo C., Talat Z., Halac M., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.41, sa.7, ss.1461-1462, 2014 (SCI-Expanded) identifier identifier identifier

44. FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection

Aksoy S. Y., Asa S., Ozhan M., Ocak M., Sager M. S., Erkan M. E., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.41, sa.3, ss.556-564, 2014 (SCI-Expanded) identifier identifier identifier

45. The Diagnostic Efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with 111In-Pentetrotide in the Detection of Neuroendocrine Tumours.

Koçyiğit Deveci E., Ocak M., Bozkurt M., Türker S., KABASAKAL L., Uğur Ö.
Mol Imaging Radionucl Ther , sa.22, ss.76-84, 2013 (Hakemli Dergi)

46. Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: A comparison of lesions with 18F-FDG-PET and MIBI images

Sager S., Kabasakal L., Ocak M., Maecke H., Uslu L., Halac M., et al.
Nuclear Medicine Communications , cilt.34, sa.12, ss.1190-1195, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

47. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer

Ocak M., Demirci E., Kabasakal L., Aygun A., Tutar R. O., Araman A., et al.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.34, sa.11, ss.1084-1089, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

48. Gastroenteropankreatik Nöroendokrin Tümörlerde Peptid Reseptör Radyonüklit Tedavi ve Y-90 Mikroküre Tedavisi

KABASAKAL L., Ocak .
Turkiye Klinikleri J Med Oncol-Special Topics , sa.6, ss.38-45, 2013 (Hakemli Dergi)

49. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results

Demirci E., Ocak M., Kabasakal L., Araman A., Ozsoy Y., Kanmaz B.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.34, sa.8, ss.727-732, 2013 (SCI-Expanded) identifier identifier identifier

50. Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting

Rangger C., Helbok A., Ocak M., Radolf T., Andreae F., Virgolini I. I., et al.
ANTICANCER RESEARCH , cilt.33, sa.4, ss.1537-1546, 2013 (SCI-Expanded) identifier identifier identifier

51. Appearance of intracranial meningioma in FDG and 68Ga-DOTATOC PET/CT.

YILMAZ S., Ocak M., Asa S., Gülsen F., HALAC M., Kabasakal L.
Revista espanola de medicina nuclear e imagen molecular , cilt.32, ss.60-1, 2013 (SCI-Expanded) identifier identifier identifier

52. The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions

Yilmaz S., Ocak M., Asa S., Aliyev A., Ozhan M., Halac M., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.39, sa.10, ss.1660-1661, 2012 (SCI-Expanded) identifier identifier

53. Comparison of Ga-68-DOTATATE and Ga-68-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Kabasakal L., Demirci E., Ocak M., Decristoforo C., Araman A., Ozsoy Y., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.39, sa.8, ss.1271-1277, 2012 (SCI-Expanded) identifier identifier identifier

54. 177Lu-[DOTA0, Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors

Yeyin N., Toklu T., Demirci E., Kabasakal L., Aygun A., Ocak M., et al.
JOURNAL OF NUCLEAR MEDICINE , cilt.53, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

55. Initial experience of biological stability and image timing of Ga-68 DOTANOC in somatostatin receptor (sstr) expressing organ and tumor

Ocak M., Kabasakal L., Demirci E., Aygun A., Ozcan R., Kanmaz B.
JOURNAL OF NUCLEAR MEDICINE , cilt.53, 2012 (SCI-Expanded) identifier

56. Diagnostic impact of 68Ga-DOTA-TATE PET/CT imaging in the detection of recurrent or metastatic medullary thyroid carcinoma and elevated calcitonin levels

Aliyev A., Ocak M., Kabasakal L., Decristoforo C., Demirci E., Yilmaz S., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

57. Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET/CT imaging in the same patient group with Neuroendocrine Tumors

Demirci E., Ocak M., Kabasakal L., Decristoforo C., Gunes B., Arslan E., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

58. 99mTc-EDDA/HYNIC-TATE scintigraphy: Results of 1 year experience in Turkey

Asa S., Ekmekcioglu O., Ocak M., Decristoforo C., Kabasakal L., Sager S., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

59. Radio labelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system

Petrik M., Knetsch P. A., Knopp R., Imperato G., Ocak M., von Guggenberg E., et al.
NUCLEAR MEDICINE COMMUNICATIONS , cilt.32, sa.10, ss.887-895, 2011 (SCI-Expanded) identifier identifier identifier

60. Early and Late 68Ga-DOTA-NOC PET/CT in somatostatin receptor (sstr) expressing organ and tumour

Demirci E., Ocak M., Kabasakal L., Decristoforo C., Ozsoy Y., Araman A., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

61. 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET in neuroendocrine tumors: First year experience in Turkey

Demirci E., Ocak M., Kabasakal L., Gunes B., Decristoforo C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

62. 177Lu-DOTA-TATE in Peptide Receptor Radionuclide Therapy: first year experience in Turkey

Kabasakal L., Demirci E., Ocak M., Decristoforo C., Papilla C., Araman A., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

63. The Diagnostic Efficiency of Tc-99m-HYNIC-octreotate SPECT-CT in Comparison with In-111-pentetrotide in the Detection of Neuroendocrine Tumours

Deveci E. K., Ocak M., Turker S., Kabasakal L., Ugur O.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

64. The value of Tc-99m HYNIC-TATE SPECT/CT in patients with recurrent or metastatic Medullary Thyroid Carcinoma

Asa S., Ekmekcioglu O., Ocak M., Decristoforo C., Arslan E., Kabasakal L., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

65. Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT imaging in the same patient group with Neuroendocrine Tumors

Demirci E., Ocak M., Kabasakal L., Decristoforo C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

66. 99m Tc-HYNIC-TATE in detection of well differantiated thyroid cancer with negative radioiodine uptake

Asa S., Ekmekcioglu O., Ocak M., Decristoforo C., Arslan E., Kabasakal L., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

67. Intraoperative Localization of Recurrent Medullary Carcinoma of the Thyroid Using Tc-99m HYNIC-TATE and a Surgical Gamma Probe

Aliyev A., Ocak M., Kabasakal L., Haciyev Y., Ozhan M., Vural O., et al.
CLINICAL NUCLEAR MEDICINE , cilt.36, sa.9, ss.831-833, 2011 (SCI-Expanded) identifier identifier identifier

68. Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607

Ocak M., Helbok A., Rangger C., Peitl P. K., Nock B. A., Morelli G., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, sa.8, ss.1426-1435, 2011 (SCI-Expanded) identifier identifier identifier

69. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative

Ocak M., Helbok A., von Guggenberg E., Ozsoy Y., Kabasakal L., Kremser L., et al.
Nuclear Medicine and Biology , cilt.38, sa.2, ss.171-179, 2011 (SCI-Expanded) identifier identifier identifier

70. Impurity in 68Ga-peptide preparation using processed generator eluate

Petrik M., Ocak M., Rupprich M., Decristoforo C.
Journal of Nuclear Medicine , cilt.51, sa.3, ss.495, 2010 (SCI-Expanded) identifier identifier identifier

71. Full automation of Ga-68 labelling of DOTA-peptides including cation exchange prepurification

Ocak M., Antretter M., Knopp R., Kunkel F., Petrik M., Bergisadi N., et al.
APPLIED RADIATION AND ISOTOPES , cilt.68, sa.2, ss.297-302, 2010 (SCI-Expanded) identifier identifier identifier

72. Comparision of biological stability of Lu-177-DOTA-minigastrin derivatives and determination of enzymatic cleavage site

Ocak M., Helbok A., von Guggenberg E., Ozsoy Y., Bergisadi N., Kabasakal L., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.36, 2009 (SCI-Expanded) identifier

73. Fully automated synthesis of radiolabelled peptides using a disposable cassette system

Petrik M., Ocak M., Knopp R., von Guggenberg E., Haubner R., Decristoforo C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.36, 2009 (SCI-Expanded) identifier

74. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: Preclinical evaluation

von Guggenberg E., Sallegger W., Helbok A., Ocak M., King R., Mather S. J., et al.
Journal of Medicinal Chemistry , cilt.52, sa.15, ss.4786-4793, 2009 (SCI-Expanded) identifier identifier identifier

75. 177Lu-DOTA-CYCLOGASTRIN: STABILITY ASSESSMENT AND EVALUATION IN VITRO

Ocak M., Decristoforo C., Rangger C., Helbok A., Sallegger W., von Guggenberg E.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS , cilt.52, 2009 (SCI-Expanded) identifier

76. QUALITY CONTROL OF Ga-68, In-111, Y-90 AND Lu-177 LABELED DOTA-DERIVATISED PEPTIDE ANALOGS USING A COMBINATION OF HPLC AND TLC

Ocak M., Decristoforo C., Bergisadi N., Kabasakal L., von Guggenberg E.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS , cilt.52, 2009 (SCI-Expanded) identifier

77. 68Ga-LABELLING OF PEPTIDES USING DIFFERENT STRATEGIES FOR A DISPOSABLE CASSETTE SYSTEM

Ocak M., Petrik M., Knopp R., von Guggenberg E., Bergisadi N., Decristoforo C.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS , cilt.52, 2009 (SCI-Expanded) identifier

78. Comparison of in-111 octreotide scintigraphy with tc-99m hynic-toc/tate scintigraphy in the same patient group for diagnosis of somatostatin receptor expressing tumors

Sager S., Kabasakal L., Yimaz S., Ocak M., Sanli Y., Maecke H., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.33, 2006 (SCI-Expanded) identifier

79. Optimization of radiolabelling efficiency of [DOTA0, Tyr3] octreotate with 177Lu, 90Y, 111In

Ocak M., Kabasakal L., Uslu E., Decristoforo C., Mut S., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.33, 2006 (SCI-Expanded) identifier

80. Somatostatin scintigraphy in patients with cushing's syndrome (preliminary data)

Sager S., Kabasakal L., Ocak M., Halac M., Nisli C., Maecke H., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.33, 2006 (SCI-Expanded) identifier

81. Clinical Experience with TC-99m Hynic-Toc and Hynic-Tate Octreotid Scintigraphy in the Follow-Up of Thyroid Cancers

Sager S., Kabasakal L., Halac M., Kasikcioglu D., Ocak M., Maecke H., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.32, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

82. Comparison of TC-99m Hynic-Octreotide and TC-99m Hynic-Octreotate in the same Patient Group with Somatostatin Receptor Expressing Tumors

Kabasakal L., Sager S., Ocak M., Maecke H., Nisli C., Onsel C., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.32, 2005 (SCI-Expanded) identifier

83. Clinical Value of TC-99M Hynic-Octreotide and TC-99M Hynic-Octreotate Scintigraphy in Patients with Somatostatin Expressing Tumours

Sager S., Kabasakal L., Ocak M., Nisli C., Maecke H., Onsel C., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.32, 2005 (SCI-Expanded) identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 62

1. Ac-225-DOTATATE ile Peptit-Reseptör Radyonüklit Tedavisi (PRRT): İlk Sonuçlar ve Progresyonsuz Sağkalıma Katkısı

Beydağı G., Demirci E., Alan-Selçuk N., Ocak E. M., Toklu T., Akçay K., et al.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 27 - 31 Mart 2022, ss.17, (Özet Bildiri)

2. Metastatik Prostat Kanserinde Ac-225-PSMA ile Radyonüklit Tedavisinin Klinik Sonuçları ve Progresyonsuz Sağkalıma Katkısı

Beydağı G., Alan Selçuk N., Demirci E., Akçay K., Ocak E. M., Toklu T., et al.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 27 - 31 Mart 2022, ss.14, (Özet Bildiri) Sürdürülebilir Kalkınma

3. PSMA PET/BT’nin Sistematik Tedavilere Yanıt Değerlendirmeye Katkısı

Beydağı G., Demirci E., Alan-Selçuk N., Akçay K., Ocak E. M., Toklu T., et al.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 27 - 31 Mart 2022, ss.21, (Özet Bildiri)

4. BCS Sınıf II Olanzapin'in Çözünürlüğünün Kendiliğinden Nanoemülsifiye Olabilen Sistemlerle Arttırılması

Abdulayeva R., Mesut B., Ocak E. M.
International Battalgazi Scientific Studies Congress-V, Malatya, Türkiye, 18 - 20 Aralık 2020, ss.1, (Özet Bildiri)

5. Tasarımla Kalite Yaklaşımı ile 68GA-PSMA-11 Radyofarmasötiğinin Hazırlanması

Pehlivanoğlu H., Aygün A., Karayel E., Ocak E. M., Sönmezoğlu K., Çağlar Andaç S.
31.Ulusal Nükleer Tıp Kongresi ve 8.Balkan Nükleer Tıp Kongresi, Muğla, Türkiye, 10 - 14 Nisan 2019, ss.120, (Özet Bildiri)

6. A PRELIMINARY STUDY FOR QUALITY BY DESIGN (QbD) IN SMALL-SCALEPREPARATION OF 68GA PSMA11

Pehlivanoğlu H., Demirci E. M., Çağlar Andaç S.
1st International Symposium on Graduate Research in Science: Focus on Entrepreneurship and Innovation, İstanbul, Türkiye, 4 - 06 Ekim 2018, ss.212, (Tam Metin Bildiri)

7. ANALYTICAL QUALITY BY DESIGN IN RADIOCHEMICAL PURITY OF[68Ga]PSMA-11, A PRELIMINARY STUDY

Pehlivanoğlu H., Ocak E. M., Çağlar Andaç S.
1 st International Symposium on Graduate Research in Science Focus on Entrepreneurship and Innovation (ISGRS 2018), İstanbul, Türkiye, 4 - 06 Ekim 2018, ss.213, (Tam Metin Bildiri)

8. Comparison of F18 DOPA and Ga68 DOTA TATE in detection of recurrences or metastasis of medullary thyroid cancer

Asa S., Sönmezoğlu K., Akgün E., Razavıkhosroshahı S., Teksöz S., Ocak E. M., et al.
European Association of Nuclear Medicine Congress 2017, Vienna, Avusturya, 21 - 25 Ekim 2017, ss.1, (Özet Bildiri) Sürdürülebilir Kalkınma

9. THE ACCURACY OF 68GALLIUM-PSMA PET/CT IN PRIMARY LYMPH NODE STAGING FOR HIGH RISK PROSTATE CANCER

Obek C., DOGANCA T., Demirci E., Ocak M., Kural A. R., YILDIRIM A., et al.
Annual Meeting of the American-Urological-Association (AUA), Massachusetts, Amerika Birleşik Devletleri, 12 - 16 Mayıs 2017, cilt.197, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

10. Electrochemistry of99mTc(III) DMSA and 99mTc(V) MDP Complexes Used for Medical Diagnostic and Radiotracers

TUTAR R., TÜRKER ACAR E., ORTABOY S., OCAK DEMİRCİ E. M., SÖNMEZOĞLU K., KABASAKAL L., et al.
2nd International Turkic World Conference on Chemical Sciences and Technologies, Üsküp, Makedonya, 26 - 30 Ekim 2016, ss.67, (Özet Bildiri)

11. 18F-fluorocholine PET/CT imaging is useful in localization of hyper-functioning parathyroid tissue in primary hyperparathyroidism: a comparative study with 99mTc-MIBI SPECT/CT and neck ultrasonography

Sonmezoglu K., Vatankulu B., Ocak M., Tutar R. O., Pehlivanoglu H., Karayel E., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

12. Preparation of 18F-Fluoromethylcholine in a fully automated radiochemical synthesizer: a tertiary university hospital experience

Karayel E., Pehlivanoglu H., Aygun A., Tutar R., Kurt A., Ocak M., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

13. Lu-177-DOTA-TATE therapy in patients with NETs: Response to treatment and long-term survival update

Demirci E., Sahin O. E., Ocak M., Aygun A., Uslu I., Kabasakal L.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

14. Peptide receptor radionuclide therapy in malignant pheochromocytoma and paraganglioma treatment

Nematyazar J., Vatankulu B., Demirci E., Asa S., Ocak M., Uslu U., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

15. Preparation of (F-18)FDOPA in a fully automated radiochemical synthesizer: a tertiary university hospital experience

Pehlivanoglu H., Karayel E., Aygun A., Tutar R., Kurt A., Ocak M., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

16. Biodistribution patterns of Lu177-DKFZ-PSMA617 and Ga68-DKFZ-PSMA11 in the same patient group

Yeyin N., Sahin O. E., Vatankulu B., Toklu T., Demirci E., Aygun A., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

17. Normal Distribution Pattern and Physiological Variants of Ga-68-PSMA PET/CT

Demirci E., Sahin O., Ocak M., Akovali B., Nematyazar J., Kabasakal L.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

18. 68Ga-PSMA HBED-CC PET/CT imaging may be useful in detection of differentiated thyroid cancer: a comparative study with 68Ga-DOTA-TATE PET/CT and 18F-FDG PET/CT imaging

Vatankulu B., Akgun E., Ocak M., Demirci E., Uslu L., Sager S., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

19. Effects of Lutetium-177 PSMA-i and Radioiodine Therapy on Salivary and Lacrimal Glands

Sahin O. E., Vatankulu B., Akyel R., Nematyazar J., Demirci E., Pehlivan H., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, İspanya, 15 - 19 Ekim 2016, cilt.43, (Özet Bildiri) identifier

20. Cervical lymph node metastases is not an uncommon finding in Ga-68-DKFZ-PSMA-11 PET/CT imaging in patients with prostate cancer

Nematyazar J., Şahin O. A., Razavi B., DEMIRCI E., Aygün A., Ocak M. T., et al.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

21. Pre-therapy Initial Dosimetry Results of Lu-177-DOTA-617-PSMA In Castration Resistant Prostate Cancer

Abuqbeitah M. M., Yeyin N., Aygün A., Demirci E., Ocak M. T., Demir M., et al.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

22. Dosimetry Results of Lu-177-DKFZ-PSMA-617 Treatment in Castration Resistant Prostate Cancer Patients

Yeyin N., Mohammad A., Kabasakal L., DEMIRCI E., Aygün A., Ocak M. T., et al.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

23. Evaluation of in vivo and in vitro stability of Lu-177-DKFZ-617 for systemic radionuclide therapy in patients with castration resistant prostate cancer

Ocak M. T., Aygün A., Yeyin N., DEMIRCI E., Karayel E., Araman A., et al.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

24. Differences in biodistribution of Lu-177-DKFZ-PSMA-617 and Ga-68-DKFZ-PSMA-11 in the same patient group

Şahin O. A., Nematyazar J., Razavi B., Yeyin N., Aygün A., Ocak M. T., et al.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri) identifier

25. Diagnostic value of (68)Ga - PSMA PET/CT in biochemical recurrence of prostate carcinoma with low PSA levels

Demirci E., Nematyazar J., Akyel R., Razavi B., Aygün A., Ocak M. T., et al.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Almanya, 10 - 14 Ekim 2015, cilt.42, (Özet Bildiri) identifier

26. Ga-68-PSMA PET/CT imaging in patients with renal cell carcinoma: initial experience

Nematyazar J., Razavi B., Akyel R., Demirci E., OCAK ., Aygün A., et al.
EANM'14, Göteborg, İsveç, 18 - 22 Ekim 2014, ss.350, (Tam Metin Bildiri)

27. Evaluation of Ga-68-PSMA PET/CT imaging in patients with prostate cancer and comparison with bone scan

Razavi B., Nematyazar J., Akyel R., Demirci E., OCAK M., Aygün A., et al.
EANM'14, Göteborg, İsveç, 18 - 22 Ekim 2014, ss.3392, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

28. Evaluation of Ga-68-PSMA PET/CT imaging in patients with prostate cancer and value of early pelvic imaging

Akyel R., Demirci E., OCAK M., Nematyazar J., Aygün A., Halaç M., et al.
EANM'14, Göteborg, İsveç, 18 - 22 Ekim 2014, ss.235, (Özet Bildiri) Sürdürülebilir Kalkınma

29. 177Lu-DOTA-TATE therapy in patients with NETs: Toxicity, response and prognostic indicators

Demirci E., Ocak M., Kabasakal L., Aygun A., Araman A., Uslu I.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Gothenburg, İsveç, 18 - 22 Ekim 2014, cilt.41, (Özet Bildiri) identifier

30. Multi-modal folate-targeted imaging of intraperitoneal ovarian tumors in mice

Gillman A., Ocak ., Bresee J., Zhang L., Mueller C., Vlad A., et al.
Society of Nuclear Medicine and Molecular Imaging, St.Louis, Amerika Birleşik Devletleri, 7 - 11 Haziran 2014, cilt.55, ss.500, (Tam Metin Bildiri)

31. Preclinical evaluation of the PET imaging radiotracer, F18-ML-10, for early detection of solid tumor response to chemotherapy

Demirci E., Ahmed R., Ocak ., Anderson C., Mountz J.
Society of Nuclear Medicine and Molecular Imaging, St.Lois, Amerika Birleşik Devletleri, 7 - 11 Haziran 2014, cilt.55, sa.1, ss.1066, (Tam Metin Bildiri)

32. Evaluation of 64Cu- and 68Ga-NODAGA-c(RGDyK) in a rodent inflammatory paw model

Ocak ., Demirci E., Day K., Latoche J., Liu J., Anderson C.
Society of Nuclear Medicine and Molecular Imaging, St.Louis, Amerika Birleşik Devletleri, 7 - 11 Haziran 2014, cilt.55, ss.1222, (Tam Metin Bildiri)

33. Transmucosal delivery of dimenhydrinate to rabbits employing mucoadhesive patch.

YILDIZ PEKÖZ A., OKYAR A., OCAK DEMİRCİ E. M., KAPTAN E., TEKELİ F., ERDAL M. S., et al.
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology,, Lizbon, Portekiz, 31 Mart - 03 Nisan 2014, ss.269-270, (Tam Metin Bildiri)

34. Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET/CT in Patients with Differentiated Thyroid Cancer

Demirci E., KABASAKAL L., Ocak ., Aygün A., Halaç M., KANMAZ M. B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2013, ss.404, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

35. Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours

Yilmaz s., Demirci E., Ocak M., Aygün A., Halaç M., Sager S., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2013, ss.588, (Tam Metin Bildiri)

36. Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE PET/CT

Demirci E., Ocak M., Yeyin N., Asa S., Aygün A., Halaç M., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2013, sa.39, ss.517, (Tam Metin Bildiri)

37. 177Lu-[DOTA0,Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors

Yeyin N., Demirci E., Toklu T., KABASAKAL L., Aygün A., Ocak M., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2013, ss.306, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

38. Comparison of I-123 MIBG Scintigraphy with Somatostatin Receptor Scintigraphy Using Tc-99m HYNIC TATE in Neuroblastoma Patients

Uslu L., KABASAKAL L., Ocak ., Tuysuz G., Celkan T., Apak H., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2013, ss.586, (Tam Metin Bildiri)

39. Tc-99m mebrophenin hepatobiliary scintigraphy for assessment of lobar functional liver status by liver mebrophenin clearance rate in patients who will undergo Y-90-microsphere treatmen

Kabasakal L., Yilmaz S., Tanyildizi H., Ocak M., Ozcan R., Aygun A., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, Fransa, 19 - 23 Ekim 2013, cilt.40, (Özet Bildiri) identifier

40. Comparison of tumour and whole body absorbed doses of 177-Lu- DOTA-TATE and Lu-177 DOTA-NOC treatment in the same patient group

Yeyin N., Kabasakal L., Akyel R., Ocak M., Toklu T., Selcuk N., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, Fransa, 19 - 23 Ekim 2013, cilt.40, (Özet Bildiri) identifier

41. Relationship of tumor absorbed doses of 177Lu-DOTA-TATE treatment and uptake in pre-therapeutic Ga68 DOTA-TATE PET/CT imaging

Demirci E., Kabasakal L., Yeyin N., Ocak M., Toklu T., Selcuk N., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, Fransa, 19 - 23 Ekim 2013, cilt.40, (Özet Bildiri) identifier

42. Biological Stabilization Studies of 68Ga DOTA-NOC Peptide via In Vitro Blood and Urine Samples By Using HPLC Analysis

TUTAR R., KABASAKAL L., DEMİRCİ E., Aygün A., OCAK E. M., KANMAZ M. B.
IUPAC 44th World Chemistry Congress, İstanbul, Türkiye, 11 - 16 Ağustos 2013, ss.797, (Tam Metin Bildiri)

43. A pharmaceutical radiochemical agent 99mtc-bromo-hida kit preparation and quality control via c-18 sep-pak cartridges and thin-layer chromatography for radioimaging

Özcan Tutar R., Aygün A., Ocak M., Kabasakal L., ATUN G., Araman A., et al.
IUPAC 44th World Chemistry Congress, Türkiye, 1 - 04 Ağustos 2013, ss.1302, (Tam Metin Bildiri)

44. Assessment of lobar functional liver status by liver mebrophenin clearance rate using Tc-99m mebrofenin hepatobiliary scintigraphy

Yılmaz S., Ekmekçioğlu Ö., Tanyıldızı H., TUTAR R., OCAK E. M., Aygün A., et al.
SNMMI Annual Meeting, Vancouver, Bc, Kanada, 8 - 12 Haziran 2013, ss.590, (Özet Bildiri)

45. Evaluation of 64Cu-DBCO-CB-TE1K1P-c(RGDyK) and 64Cu-DBCO-CB-TE1A1P-c(RGDyK) for PET imaging of metastatic bone disease

OCAK M., Beaino W., Zeng D., White A., Cai Z., Anderson C.
SNMMI 2013, Vancouver, Bc, Kanada, 8 - 12 Haziran 2013, cilt.54, sa.2, ss.1059, (Tam Metin Bildiri)

46. Hepatobiliyer Sistem Sintigrafisinde Tc-99m Mebrofenin Kullanılarak Farklı Klirens Hesaplama Metodlarının Karşılaştırılması

Tanyıldızı H., KABASAKAL L., TUTAR R., Yılmaz S., Yeyin N., Aygün A., et al.
25.Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 6 - 10 Nisan 2013, ss.96-97, (Tam Metin Bildiri)

47. Tc-99m Mebrofenin hepatobiliyer sintigrafi yardımıyla mebrofenin klirens hızının hesaplanarak lobar karaciğer fonksiyonlarının değerlendirilmesi

Yılmaz Aksoy S., Tanyıldızı H., Ekmekçioğlu Ö., Özcan Tutar R., Ocak M., Aygün A., et al.
25.Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 1 - 04 Nisan 2013, ss.15, (Özet Bildiri)

48. Radyofarmasötik 99mTc-HIDA kiti hazırlanması ve kalite kontrol çalışmasının yapılması

Aygün A., Özcan Tutar R., Ocak M., Kabasakal L., ATUN G., Araman A., et al.
25.Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 1 - 04 Nisan 2013, ss.15, (Özet Bildiri)

49. 177Lu-[DOTA0,Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors

Yeyin N., Demirci E., Toklu T., Kabasakal L., Aygun A., Ocak M., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2012, cilt.39, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

50. Comparison of I-123 MIBG Scintigraphy with Somatostatin Receptor Scintigraphy Using Tc-99m HYNIC TATE in Neuroblastoma Patients

Uslu L., Kabasakal L., Ocak M., Tuysuz G., Celkan T., Apak H., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2012, cilt.39, (Özet Bildiri) identifier

51. Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE PET/CT

Demirci E., Ocak M., Yeyin N., Asa S., Aygun A., Halac M., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2012, cilt.39, (Özet Bildiri) identifier

52. Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours

Yilmaz S., Demirci E., Ocak M., Aygun A., Halac M., Sager S., et al.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2012, cilt.39, (Özet Bildiri) identifier

53. Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET/CT in Patients with Differentiated Thyroid Cancer

Demirci E., Kabasakal L., Ocak M., Aygun A., Halac M., Kanmaz B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, İtalya, 27 - 31 Ekim 2012, cilt.39, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

54. Lu-177 DOTA-TATE ile peptit reseptör radyonüklid tedavisinde absorbe doz değerleri

Yeyin N., Toklu T., ÇAVDAR İ., Tanyıldızı H., Demirci E., OCAK DEMİRCİ E. M., et al.
24. Ulusal Nükleer Tıp Kongresi, Antalya, Türkiye, 4 - 08 Nisan 2012, ss.20, (Tam Metin Bildiri)

55. Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor

Demirci E., Kabasakal L., Ocak M., Aygun A., Ozcan R., Decristoforo C., et al.
9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Copenhagen, Danimarka, 7 - 09 Mart 2012, cilt.96, ss.26, (Özet Bildiri) identifier

56. Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors

Kabasakal L., Demirci E., Ocak M., Aygun A., Decristoforo C., Uslu I., et al.
9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Copenhagen, Danimarka, 7 - 09 Mart 2012, cilt.96, ss.38, (Özet Bildiri) identifier

57. Detection of somatostatin receptor-positive tumours using Tc-99m-EDDA/HYNIC-NOC and comparison with Tc-99m-EDDA/HYNIC-TATE in the same patient group

Ocak M., Ekmekcioglu O., Kabasakal L., Decristoforo C., Asa S., Araman A., et al.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Avusturya, 9 - 13 Ekim 2010, cilt.37, (Özet Bildiri) identifier

58. Comparison of 99mTc-EDDA/HYNIC-TATE and 111 In Octreotide in the same patient group with somatostatin receptor expressing tumors

Ekmekcioglu O., Ocak M., Kabasakal L., Araman A., Decristoforo C., Nisli S., et al.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Avusturya, 9 - 13 Ekim 2010, cilt.37, (Özet Bildiri) identifier

59. Comparison and improvement of the metabolic stability of CCK-2 receptor targeting peptides, a collaborative project under COST BM0607

Ocak M., Rangger C., Klingler M., Kabasakal L., Decristoforo C., von Guggenberg E.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Avusturya, 9 - 13 Ekim 2010, cilt.37 identifier

60. Comparison of (68)Ga-DOTA, Tyr(3), Thr(8) -octreotide PET/CT and (99m)Tc-HYNIC, Tyr(3), Thr(8)-octreotide SPECT/CT in neuroendocrine tumors

Gunes B., Ocak M., Kabasakal L., Araman A., Decristoforo C., Ekmekcioglu O., et al.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Avusturya, 9 - 13 Ekim 2010, cilt.37, (Özet Bildiri) identifier

61. Can Ga-67-Dowex 50 W be used as an alternative compound for colonic transit evaluation?

Savas O., Cabuk M., Cevher E., Aydemir S., Ocak M., Sen F., et al.
20th Annual Congress of the European-Association-of-Nuclear-Medicine, Copenhagen, Danimarka, 01 Ocak 2007, (Özet Bildiri) identifier

62. Metilen mavisi ile stabilize edilmiş HMPAO kitinin bölünmüş dozlardaki işaretleme verimliliği ve kararlılık süresinin kromatografik yolla incelenmesi

ADAY H. S., OCAK DEMİRCİ E. M., ADAY A., TÜRKMEN C., KABASAKAL L., ÜNAL S. N.
7th International Congress of Nuclear Oncology & 18th National Congress of the Turkish Society of Nuclear Medicine, Antalya, Türkiye, 13 - 17 Mayıs 2006, cilt.15, sa.1, (Özet Bildiri)
Kitaplar 8

1. Radiopharmaceuticals for Radionuclide Therapy

Ocak E. M., Demirci E., R. Nedrow J., Krimins R.
Handbook of Nuclear Medicine and Molecular Imaging for Physicists, Michael Ljungberg, Editör, Taylor eBookstore , Florida, ss.39-53, 2022

2. Karaciğerin Primer ve Sekonder Tümörlerinde Transarteriyel Radyoembolizasyon: Radyofarmasötikler

OCAK .
Karaciğerin Primer ve Sekonder Tümörlerinde Löko-Rejyonel Tedavi Seçenekleri; Endikasyon, Tedavi ve Takip, Numan F., Editör, Türkiye Türkiye Klinikleri Yayınevi, Ankara, ss.75-79, 2020

3. SPECT Radyofarmasötikleri İşaretleme Yöntemleri ve Radyasyon Korunması

OCAK M.
Radyofarmasotiklerin Uretiminde ve Klinik Kullaniminda Radyasyon Korunmasi - 2019, Demir M., Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.56-65, 2019

4. Radyonüklit Tedavide Kullanılan Radyofarmasötiklerin Temel Özellikleri ve Üretimi

OCAK .
Radyonüklit Tedavi, Bekiş R., Polack B., Bozkurt MF, Editör, O'tıp Kitapevi Yayınları, İzmir, ss.1-20, 2019

5. Teranostik Radyofarmasötikler ve Yeni Nesil Ajanlar

OCAK M.
Nükleer Onkolojide Teranostik Uygulamalar, Prof.Dr.Zehra Özcan, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.5-10, 2018

6. Quality Control In the Production of Raiopharmaceuticals

OCAK M.
Quality Control In the Production of Raiopharmaceuticals, IAEA-TECDOC-1856, Editör, International Atomic Energy Agency, Vienna, ss.1-150, 2018

7. PET Radyofarmasötikleri

OCAK .
Uygulamalı Temel Radyofarmasi, Prof.Dr.Perihan Ünak, Prof.Dr.Gülay Durmuş Altun,Prof.Dr.Serap Teks., Editör, Nobel Tıp Kitabevleri, İstanbul, ss.159-177, 2017

8. Radyofarmasötikler

USLU İ., Ocak M.
Nükleer Tıp Ders Kitabı, Prof.Dr.Çetin Önsel, Editör, İstanbul Üniversitesi, İstanbul, ss.37-55, 2009
Diğer Yayınlar 3

1. Appearance of intracranial meningioma in FDG and 68Ga-DOTATOC PET/CT.

Sabire Y., OCAK ., asa s., Gülşen F., Halaç M., KABASAKAL L.
Diğer, ss.60-61, 2013

2. Intraoperative localization of recurrent medullary carcinoma of the thyroid using Tc-99m HYNIC-TATE and a surgical gamma probe.

Aliev A., OCAK E. M., Kabasakal L., et.al ..
Diğer, ss.831-3, 2011

3. Impurity in (68)Ga-peptide preparation using processed generator eluate.

Petrik M., OCAK E. M., Rupprich M., Decristoforo C.
Teknik Rapor, ss.495, 2010
Metrikler

Yayın

156

Yayın (WoS)

109

Yayın (Scopus)

79

Atıf (WoS)

1153

H-İndeks (WoS)

18

Atıf (Scopus)

1163

H-İndeks (Scopus)

18

Atıf (Scholar)

34

H-İndeks (Scholar)

1

Atıf (TrDizin)

3

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

3

Proje

15

Tez Danışmanlığı

3

Açık Erişim

3
BM Sürdürülebilir Kalkınma Amaçları